Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASR | P41180 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318573 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BMAPTKMT2AL3MBTL1 | |
| SCHEMBL9211792 | 0.84 | LMNA (0.56) | ALDH1A1ITGB3ITGA2BMAPTL3MBTL1 | |
| SCHEMBL1554809 | 0.82 | CA1 (0.58) | ALDH1A1MAPTATML3MBTL1CYP3A4 | |
| SCHEMBL15686273 | 0.82 | ITGB3 (0.48) | ITGB3ITGA2BMAPTKMT2AL3MBTL1 | |
| SCHEMBL5019087 | 0.81 | LMNA (0.61) | ALDH1A1KMT2APOLBL3MBTL1CA1 | |
| SCHEMBL9830162 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL20640801 | 0.80 | LMNA (0.57) | ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL15691161 | 0.80 | LMNA (0.50) | ALDH1A1ATM | |
| SCHEMBL6258143 | 0.80 | CASR (0.58) | ALDH1A1MAPTKMT2ACASRMEN1 | |
| SCHEMBL20530482 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1303510-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1189901-A1 | OXAZAHETEROCYCLES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002006248-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6326492-B1 | ANTICOAGULANT | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
| WO-2000073302-A1 | OXAZAHETEROCYCLES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | ALDH1A1 2762/4885ITGB3 445/4885ITGA2B 1587/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | ALDH1A1 2762/4885ITGB3 445/4885ITGA2B 1587/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | ALDH1A1 3782/4885ITGB3 446/4885ITGA2B 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.